<DOC>
	<DOCNO>NCT01324180</DOCNO>
	<brief_summary>H. Lee Moffitt Cancer Center Research Institute Sunshine Project Coordinator , recruit locally . The purpose trial study clinical biological effect metformin combination standard systemic chemotherapy disease ( relapse ALL ) dismal outcome , well dose escalation study find Maximum Tolerated Dose ( MTD ) metformin conjunction ALL therapy . There also analysis patient enrol trial diabetic metformin outcome good patient trial metformin antihyperglycemic .</brief_summary>
	<brief_title>Vincristine , Dexamethasone , Doxorubicin , PEG-asparaginase ( VPLD ) Metformin Relapsed Childhood Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>This phase I protocol Vincristine , Dexamethasone , Doxorubicin , PEG-asparaginase ( VPLD ) metformin conduct Sunshine Project sit child recurrent ALL . All sit eligible open study , provide agree adhere study procedure make good faith effort obtain pharmacodynamic pharmacokinetic evaluation request .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>ALL lymphoblastic lymphoma patient first high relapse . Male Female age 130 year initial diagnosis . Signed informed consent . Karnofsky / Lansky score 50 % . No known contraindication intend therapy . Prior anthracycline exposure : Patients must less 350 mg/m^2 lifetime exposure anthracycline chemotherapy . It must least 6 month since last treatment `` VPLD '' induction/reinduction type regimen ( i.e . anthracycline , steroid , asparaginase vincristine ) . Patients must adequate organ function . Adequate renal function define serum creatinine &lt; 1.5 x upper limit normal ( ULN ) age . Total bilirubin &lt; 1.5 X ULN age . Alanine transaminase ( ALT ) &lt; 5 X ULN age , unless elevation diseaserelated . Adequate cardiac function define shorten fraction &gt; 27 % echocardiogram ejection fraction &gt; 45 % gate radionuclide study . Significant renal impairment determine per investigator discretion . Patients plan receive investigational agent study . Patients plan receive anticancer therapy study . Patients active infection define : positive blood culture within 48 hour study registration ; need supplemental oxygen vasopressor within 48 hour study entry . Patient receive corticosteroid , aside dexamethasone treatment direct leukemia . Known intolerance doxorubicin , metformin , vincristine . Patients start protocol therapy prior enrollment . Patient may still enroll IT therapy give within 72 hour study enrollment part diagnostic lumbar procedure . Patients may hydroxurea first dose metformin give . Patients need continue hydroxurea study ( Patients may continue hydroxurea first dose metformin give ) . Patients creatinine 1.5 x ULN Patients must recover acute side effect prior anticancer therapy . At least 1 week prior cytotoxic chemotherapy . At least 4 week craniospinal irradiation . At least 4 month since hematopoietic stem cell transplant ( HSCT ) evidence active graftversushost disease ( GVHD ) . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ALL</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>